Enanta Pharmaceuticals, Inc.
Period Ending Sep 30, 2013 Sep 30, 2012 Sep 30, 2011
Total Revenue 32,053 41,706 41,882
Cost of Revenue - - -
Gross Profit 32,053 41,706 41,882
Operating Expenses
Research and Development 16,841 15,115 11,547
Sales, General and Admin. 6,183 5,302 5,036
Non-Recurring Items - - -
Other - - -
Operating Income 9,029 21,289 25,299
Income From Continuing Operations
Add'l Income/Expense Items 629 110 1,172
Earnings Before Interest and Tax 9,658 21,399 26,471
Interest Expense 31 - 3,161
Earnings Before Tax 9,627 21,399 23,310
Income Tax - - -
Minority Interest - - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations 9,627 21,399 23,310
Non Recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income 9,627 21,399 23,310
Preferred Stock and Other Adjustments (16,196) (20,030) (21,745)
Net Income Applicable to Common Shareholders (6,569) 1,369 1,565